Skip to Content Facebook Feature Image

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

Business

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable
Business

Business

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

2026-10-07 01:13 Last Updated At:03:25

CAMBRIDGE, England, Oct. 7, 2026 /PRNewswire/ -- Cambridge Heartwear® Limited (www.camheartwear.com) has secured a landmark £184 million tender with the National Health Service (NHS) of the UK for HeartSense®, the world's first medical-grade, multi-channel, portable, wirelessly charged ECG wearable straight to one's mobile phone, representing a significant advancement in global Medical technology, AI application and cardiovascular diagnostics. 

The agreement with the UK National Health Service Supply chain enables the deployment of advanced cardiac monitoring technology across primary and secondary care and civil service departments, empowering patients to diagnose heart rhythm problems whenever and wherever they are to prevent heart failure and strokes earlier, reduce waiting times and support a more preventative approach to Heart Disease, which can take place in the comfort of their own homes. 

HeartSense® is the world's first wearable to combine diagnostic-grade multi-channel ECG monitoring, adaptive artificial intelligence and wireless charging in a single device. Manufactured to bridge the gap in women's cardiovascular care with its ergonomic design, the technology gives healthcare professionals and patients access to continuous, real-time ECG data on a mobile phone. giving you back the control of your health at every stage. 

Engineered in Cambridge and manufactured in Britain, HeartSense® has been developed to help identify cardiovascular disease and stroke risk before conditions become acute. Its proprietary engineering and AI technology with (86 patents ) support earlier intervention, enabling clinicians to make more informed decisions and improve patient outcomes. 

The system is UKCA approved and ISO 13845 certified, with FDA 510(k) applications currently in progress. 

"We did not have a UK ECG manufacturer and reporter until now," said Professor Rameen Shakur, Founder of Cambridge Heartwear. "HeartSense® is the world's first medical-grade, AI-powered, multi-channel ECG wearable and demonstrates what can be achieved when clinicians, engineers and AI specialists work together. We want to help move healthcare towards earlier diagnosis, better prevention and improved outcomes for patients across the NHS." 

The partnership with the NHS Supply Chain allows Integrated Care Boards to deploy HeartSense® at scale, supporting the delivery of diagnostic-quality heart monitoring beyond hospital environments. The initiative is intended to reduce pressure on secondary care services while improving access to high-quality cardiac diagnostics in community settings. 

Founded by Professor Rameen Shakur, Cambridge Heartwear is a medical technology company based at Cambridge Science Park coming out of the University of Cambridge dedicated to making heart health monitoring simple, accessible and accurate. Combining medical research, engineering excellence and artificial intelligence, the company develops advanced wearable technologies that empower patients and healthcare professionals with diagnostic-quality cardiovascular insights anytime, anywhere. HeartSense® helps detect heart conditions earlier, enabling more informed clinical decision-making and better patient care.

Contact: info@camheartwear.com

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

Cambridge Heartwear Awarded £184 Million NHS Tender for World's First Medical-Grade, Wirelessly Charged, Reusable ECG Wearable

SYDNEY, Oct. 7, 2026 /PRNewswire/ -- FXT, the global online trading platform for forex and CFD traders, has been named an official nominee in seven Global categories at the prestigious Finance Magnates Awards 2026. They include Broker of the Year 2026, Most Innovative Broker 2026,  Most Trusted Broker 2026 and Best Overall Broker 2026.

Finance Magnates has reported on the online trading industry since 2009 and its annual awards are among the most closely watched in the sector. Results are decided equally by a community vote of traders and industry professionals and an expert judging panel.
Voting closes 16 October 2026 and winners will be announced at a gala dinner on 6 November 2026.

FXT has been trusted by more than 100,000 traders since 2014 and offers negative balance protection, segregated client funds and multi-layered account security.

Traders can access forex, indices, stocks, metals and energies through MT4, MT5, FXT WebTrader and the FXT Mobile App with raw spreads from 0.0 pips.

FXT AI runs on 100% proprietary technology inside every FXT account. Its Market Reader, Trade Mentor and Risk Monitor agents help traders read the market, learn from their trade history and understand their risk.

Adam Phillips CEO at FXT said. "Standing among the global industry leaders is a massive validation of our vision and technology. Half of this outcome is decided directly by the trading community, so this recognition belongs to our clients as much as to us. If FXT has earned your trust, we would value your vote."

Explore the platform and FXT AI at fxtrading.com. Vote for FXT at awards.financemagnates.com/voting by choosing the one category you feel fits us best.

About FXT

FXT is a global multi-asset CFD broker built for traders who want greater clarity, control and choice when markets move. Since 2014, more than 100,000 traders worldwide have used FXT to access 200+ instruments across forex, indices, commodities and share CFDs. FXT supports trading through MT4, MT5, FXT WebTrader and the FXT Mobile App, with FXT AI built into the account experience.

FXTrading.com (FXT) is a trading name of Gleneagle Securities Pty Ltd, which is incorporated in Vanuatu and is regulated to provide financial services by the Vanuatu Financial Services Commissions (VFSC) under company number 40256.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

FXT Named a Finance Magnates Awards 2026 Official Nominee including Broker of the Year, Most Innovative Broker, Most Trusted Broker and Best Overall Broker.

FXT Named a Finance Magnates Awards 2026 Official Nominee including Broker of the Year, Most Innovative Broker, Most Trusted Broker and Best Overall Broker.

Recommended Articles